The targeted drug delivery industry focuses on the precise administration of medications, minimizing side effects while maximizing therapeutic outcomes. Companies in this sector, ranging from biotech startups to established manufacturers, innovate technologies that enhance drug absorption at specific sites within the body. They employ advanced materials such as nanoparticles and liposomes, which offer significant improvements over traditional methods. As research continues to yield astonishing breakthroughs, the industry is set to expand, paving the way for more efficient therapies tackling complex conditions, particularly in oncology. The emphasis on patient-centric approaches and improved delivery systems signifies a transformative shift in healthcare.

The companies featured in this listing vary in size, ranging from small firms with less than 50 employees to medium enterprises boasting over 500 staff. Headquartered in regions like Israel, Canada, France, and the USA, these firms were founded between 1969 and 2021. They excel in developing specialized products such as injectable therapies, innovative drug delivery devices, and advanced biopharmaceutical formulations, underscoring their expertise in targeted treatments across various medical fields, especially oncology and immunotherapy.

Continue reading to discover the top targeted drug delivery companies.

Top 21 Targeted Drug Delivery Companies

1. Biond Biologics Ltd

• Website: biondbio.com
• Ownership type: Venture Capital
• Headquarters: Misgav, North, Israel
• Employee distribution: Israel 100%
• Latest funding: Series C, $15.0M, November 2021
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: biond-biologics-ltd

Biond Biologics Ltd, founded in 2016 and based in Misgav, Israel, is a biotechnology company dedicated to developing innovative therapies for cancer treatment. The company specializes in creating biological products and drug delivery platforms that specifically target immune evasion mechanisms. Biond's research is grounded in real-world patient and tumor samples, which informs their development of novel therapies. Their pipeline includes several promising candidates, such as BND-22, a first-in-class immune checkpoint inhibitor currently in phase 1 clinical trials, and BND-35, which is set to enter phase 1 trials soon. Biond has also developed the INspire platform, designed to facilitate the intracellular delivery of biologics, thereby targeting previously considered 'undruggable' intracellular targets. The company has successfully raised $15 million in Series C funding as of November 2021, indicating strong investor interest and confidence in their approach to cancer treatment.

2. ProteinQure

• Website: proteinqure.com
• Ownership type: Venture Capital
• Headquarters: Toronto, Ontario, Canada
• Employee distribution: Canada 100%
• Latest funding: Seed, $4.0M, July 2019
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: proteinqure

ProteinQure, founded in 2017 and based in Toronto, Ontario, is a biotechnology firm that specializes in the design and development of peptide-based drug delivery systems and therapeutics. The company is dedicated to advancing precision medicine by leveraging cutting-edge computational tools to create targeted treatments for various diseases, with a particular emphasis on oncology. ProteinQure's innovative approach includes the use of their proprietary platform, ProteinStudio™, which enables the design of unique peptides that can deliver therapeutic payloads in a tissue-specific manner. Their clientele includes pharmaceutical companies and research institutions seeking novel solutions for drug delivery. In 2019, ProteinQure secured $4 million in seed funding, which supports their ongoing research and development efforts in the field of targeted drug delivery.

3. Nemera

• Website: nemera.net
• Ownership type: Private Equity
• Headquarters: Fontaines-Sur-Saône, Auvergne-Rhône-Alpes, France
• Employee distribution: France 61%, United States (USA) 19%, Brazil 10%, Other 11%
• Latest funding: October 2018
• Founded year: 2015
• Headcount: 1001-5000
• LinkedIn: nemera

Nemera, founded in 2015 and based in Fontaines-Sur-Saône, France, is a private equity-owned medical device manufacturer. The company specializes in drug delivery device solutions and combination product services, catering to the pharmaceutical, biotechnology, and generic industries. With a workforce of approximately 1,390 employees, Nemera is committed to enhancing treatment efficacy and ensuring safe medication delivery. Their offerings include device development, clinical manufacturing, and innovation support, which are essential for the successful implementation of targeted drug delivery systems. The company operates globally, with a significant presence in France, the United States, Brazil, Germany, and Poland, reflecting its international reach and capability in the healthcare sector.

4. Antares Pharma Inc.

• Website: antarespharma.com
• Ownership type: Corporate
• Headquarters: Ewing Township, New Jersey, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $960.0M, April 2022
• Founded year: 1979
• Headcount: 51-200
• LinkedIn: antares-pharma-inc-

Antares Pharma Inc., based in Ewing Township, New Jersey, is a biotechnology company founded in 1979. The company is dedicated to advancing drug delivery technologies and pharmaceutical products that enhance patient experiences. Their flagship technology, ENHANZE®, utilizes a proprietary enzyme to enable the subcutaneous delivery of high-volume drugs, significantly reducing the time required for treatment administration. Antares Pharma collaborates with various pharmaceutical companies to improve treatment protocols and patient outcomes. The company has also received substantial funding, with a reported amount of $960 million in April 2022, indicating strong investor confidence in their innovative approaches to drug delivery.

5. GP-Pharm

• Website: gp-pharm.com
• Ownership type: Private
• Headquarters: L'Hospitalet De Llobregat, Catalonia, Spain
• Employee distribution: Spain 53%, Argentina 45%, Uruguay 3%
• Founded year: 2000
• Headcount: 51-200
• LinkedIn: lab.-gp-pharm

GP-Pharm is a private pharmaceutical company based in L'Hospitalet De Llobregat, Catalonia, Spain, founded in 2000. The company specializes in the development and manufacturing of injectable drugs, with a particular emphasis on innovative drug delivery systems. Their expertise includes microencapsulation techniques using liposomes, lipid nanoparticles, and microspheres, which are crucial for creating effective therapies in oncology, urology, and women's health. GP-Pharm operates a vertically integrated model, managing the entire process from research and development to market launch, including preclinical and clinical studies. They also offer contract manufacturing and development services, catering to the needs of other pharmaceutical companies. With a strong focus on international expansion, GP-Pharm collaborates with global partners to distribute their products across various regions, including Europe, the United States, and Latin America. Their facilities have been approved by multiple regulatory agencies, underscoring their commitment to quality and compliance in the pharmaceutical industry.

6. Pharmathen

• Website: pharmathen.com
• Ownership type: Private Equity
• Headquarters: Marousi, North Athens Regional Unit, Greece
• Employee distribution: Greece 96%, Other 4%
• Latest funding: $1.9B, July 2021
• Founded year: 1969
• Headcount: 1001-5000
• LinkedIn: pharmathen

Pharmathen, founded in 1969 and based in Marousi, Greece, is a pharmaceutical company that specializes in innovative drug delivery technologies and advanced pharmaceutical products. With a workforce of over 1,000 employees, Pharmathen operates globally, providing solutions that enhance patient compliance and improve healthcare outcomes. The company is particularly known for its long-acting injectables, sustained release formulations, and preservative-free ophthalmic products. Pharmathen invests significantly in research and development, with an annual budget of €35 million, and has developed a pipeline of more than 40 products. Their manufacturing facilities are approved by both the US FDA and EU authorities, ensuring high-quality production standards. Pharmathen's commitment to innovation is reflected in their extensive portfolio, which includes over 90 commercialized products sold in more than 90 countries. The company has also received substantial funding, indicating strong investor confidence in its growth and potential.

7. EnGeneIC

• Website: engeneic.com
• Ownership type: Venture Capital
• Headquarters: Lane Cove West, New South Wales, Australia
• Employee distribution: Australia 100%
• Latest funding: $150,000, April 2017
• Founded year: 2001
• Headcount: 11-50
• LinkedIn: engeneic

EnGeneIC is a biopharmaceutical company based in Lane Cove West, New South Wales, Australia, founded in 2001. The company is dedicated to the research, development, and manufacturing of targeted anti-cancer therapies using its proprietary EDV™ nanocell platform. This innovative platform allows for the direct targeting of tumors while leveraging the patient's immune system, aiming to improve treatment outcomes and reduce toxicity. EnGeneIC has developed a robust pipeline of clinical trials, focusing on various cancer types, and has garnered attention for its promising results in treating conditions like pancreatic cancer. The company has also been recognized for its intellectual property, holding over 435 granted patents worldwide related to its EDV technology. In 2017, EnGeneIC secured funding of $150,000, which supports its ongoing research and development efforts.

8. OxSonics Therapeutics

• Website: oxsonics.com
• Ownership type: Venture Capital
• Headquarters: Oxford, England, United Kingdom (UK)
• Employee distribution: United Kingdom (UK) 100%
• Latest funding: Series B, $13.1M, July 2020
• Founded year: 2013
• Headcount: 11-50
• LinkedIn: oxsonics-limited

OxSonics Therapeutics, based in Oxford, England, is a biotechnology firm founded in 2013. The company specializes in innovative cancer therapies, particularly through its proprietary SonoTran® platform. This platform enhances the delivery of anti-cancer drugs to solid tumors, addressing a critical challenge in oncology where drug penetration is often limited. OxSonics collaborates with pharmaceutical and biotech companies to optimize cancer therapies, aiming to improve treatment outcomes for patients. The company has received significant funding, with a Series B round totaling over £13 million in July 2020, which supports its ongoing research and development efforts. Their focus on creating effective drug delivery systems positions them as a notable player in the targeted drug delivery space.

9. Nano Daru

• Website: nanodaru.com
• Ownership type: Private
• Headquarters: Tehran, Tehran, Iran
• Employee distribution: Iran 100%
• Founded year: 2011
• Headcount: 201-500
• LinkedIn: nano-daru

Nano Daru, founded in 2011 and based in Tehran, Iran, is a private pharmaceutical company dedicated to the development of innovative drug delivery systems and oncology products. With a workforce of around 83 employees, the company has made significant strides in formulating advanced medications aimed at improving treatment outcomes for cancer patients. Their flagship products include Paclinab, a nanoparticle formulation of paclitaxel designed to minimize toxicity and enhance delivery, and Palbocap, a selective CDK4/6 inhibitor for breast cancer treatment. Nano Daru operates with a strong emphasis on scientific innovation and ethical practices, striving to provide effective therapeutic options for healthcare providers and patients alike. Their commitment to research and development in drug delivery technologies positions them as a relevant player in the pharmaceutical industry.

10. Vect-Horus

• Website: vect-horus.com
• Ownership type: Venture Capital
• Headquarters: Marseille, Provence-Alpes-Côte D'Azur, France
• Employee distribution: France 100%
• Latest funding: Series D, $6.4M, December 2020
• Founded year: 2005
• Headcount: 11-50
• LinkedIn: vect-horus-s-a-s-

Vect-Horus, founded in 2005 and based in Marseille, France, is a biotechnology company focused on drug delivery systems and therapeutic technologies. The company aims to enhance the transport of therapeutic and imaging agents, primarily catering to pharmaceutical and biotechnology firms. With a dedicated team of around 48 employees, mostly in research and development, Vect-Horus is actively engaged in advancing its innovative technologies. They have received significant funding, including a Series D round in December 2020, amounting to over 6 million euros. Their collaborations with academic institutions and financial partners bolster their research efforts, particularly in developing targeted delivery systems for nucleic acids like siRNAs and mRNAs. Vect-Horus's commitment to improving therapeutic delivery positions them as a notable player in the targeted drug delivery industry.

11. Nanomi

• Website: nanomi.com
• Ownership type: Private
• Headquarters: Oldenzaal, Overijssel, Netherlands
• Employee distribution: Netherlands 100%
• Founded year: 2004
• Headcount: 11-50
• LinkedIn: nanomi

Nanomi is a pharmaceutical company based in Oldenzaal, Netherlands, founded in 2004. The company focuses on developing drug delivery systems, particularly long-acting release injectable medicines. Utilizing their proprietary Microsieve technology, Nanomi produces well-defined microspheres and nanoparticles that cater to the needs of pharmaceutical companies and healthcare providers. Their products are designed to enhance patient compliance and improve therapeutic outcomes by ensuring controlled and reproducible medication delivery. As a subsidiary of Lupin Limited, Nanomi operates under stringent quality standards and has established itself as a center of excellence in the field of complex injectables. The company is committed to innovation and quality, making significant contributions to the pharmaceutical industry.

12. RS Research

• Website: rsresearch.net
• Ownership type: Corporate
• Headquarters: Pendik, İstanbul, Turkey
• Employee distribution: Turkey 100%
• Latest funding: Other (Grant), $109,000, March 2024
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: rs-research

RS Research is a biotechnology start-up based in Pendik, İstanbul, Turkey, founded in 2015. The company is dedicated to discovering and developing smart nanomedicines aimed at improving targeted chemotherapy treatments. Their innovative approach focuses on enhancing the efficacy of cancer therapies while minimizing side effects for patients. RS Research's primary customers include healthcare providers and patients seeking advanced cancer treatment options. The company has made significant strides in the industry, evidenced by their participation in clinical trials and presentations at notable medical congresses, such as the European Society for Medical Oncology (ESMO). They have also secured funding, including a recent grant of approximately $108,734 in March 2024, which supports their ongoing research and development efforts. Their proprietary Sagitta® drug delivery technology is designed to optimize therapeutic outcomes, showcasing their commitment to advancing cancer treatment.

13. Genevant Sciences

• Website: genevant.com
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 96%, United States (USA) 4%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: genevant

Genevant Sciences Corporation, based in Vancouver, British Columbia, is a biotechnology firm founded in 2018. The company specializes in nucleic acid delivery technologies, focusing on lipid nanoparticles (LNPs) to enhance the delivery of mRNA and siRNA therapies. With a strong emphasis on innovation, Genevant has developed multiple proprietary platforms that address the challenges of delivering nucleic acid medicines effectively. Their expertise is reflected in their extensive patent portfolio, which includes over 700 patents related to lipid compositions and formulations. Genevant has collaborated with notable companies in the pharmaceutical and biotechnology sectors, working on projects that aim to transform the treatment landscape for various diseases. Their technology has been validated through clinical programs involving more than 600 subjects, showcasing their commitment to advancing nucleic acid therapies.

14. SOTIO Biotech

• Website: sotio.com
• Ownership type: Private Equity
• Headquarters: Prague, Prague, Czech Republic
• Employee distribution: Czech Republic 83%, United States (USA) 6%, Switzerland 6%, Other 5%
• Latest funding: $316.6M, December 2021
• Founded year: 2010
• Headcount: 201-500
• LinkedIn: sotio-a.s.

SOTIO Biotech, founded in 2010 and based in Prague, Czech Republic, is a biotechnology firm dedicated to advancing cancer treatments. The company specializes in clinical-stage research, focusing on immunotherapies that aim to improve patient outcomes in oncology. SOTIO's pipeline includes innovative products such as IL-15 superagonists and antibody-drug conjugates (ADCs), which are designed to target and treat various solid tumor types. The company collaborates with healthcare providers and research institutions globally, enhancing its capabilities in research, development, and clinical trials. SOTIO has also secured significant funding, with a reported amount of over $316 million in its last funding round in December 2021, indicating strong investor confidence in its potential to deliver impactful therapies.

15. Thermosome

• Website: thermosome.com
• Ownership type: Venture Capital
• Headquarters: Planegg, Bavaria, Germany
• Employee distribution: Germany 100%
• Latest funding: Seed, $2.2M, April 2016
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: thermosome

Thermosome is a biotechnology firm based in Planegg, Bavaria, Germany, founded in 2015. The company is dedicated to advancing cancer treatment through targeted tumor therapy and immune stimulation. Their primary focus is on developing innovative drug delivery systems, with a notable product being THE001, a thermosensitive liposomal formulation of doxorubicin. This product aims to enhance treatment efficacy for patients suffering from locally advanced soft tissue sarcoma. Thermosome's approach utilizes proprietary thermosensitive liposomes that release drugs in response to localized heating, allowing for higher concentrations of medication directly at the tumor site. This method not only improves clinical outcomes but also addresses challenges such as drug resistance. The company has received seed funding of approximately €2.17 million, which supports its research and development efforts in the pharmaceutical sector. Thermosome's commitment to improving cancer therapies positions it as a relevant player in the targeted drug delivery industry.

16. Acuitas Therapeutics

• Website: acuitastx.com
• Ownership type: Private
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Founded year: 2009
• Headcount: 51-200
• LinkedIn: acuitastx

Acuitas Therapeutics is a biotechnology firm based in Vancouver, British Columbia, founded in 2009. The company specializes in developing lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, which are essential for the effective delivery of RNA-based medicines. Acuitas collaborates with pharmaceutical and biotechnology companies, as well as academic institutions, to bring innovative therapies to market. Their technology has been clinically validated, notably through their partnership with Alnylam Pharmaceuticals for Onpattro™, an RNAi therapeutic approved in 2018. Additionally, Acuitas played a significant role in the development of the COVID-19 vaccine COMIRNATY® in collaboration with BioNTech and Pfizer. This involvement highlights their expertise in mRNA therapeutics and their commitment to addressing critical health challenges. Acuitas continues to explore new applications for their LNP technology, including vaccines for infectious diseases and immunomodulation therapies for cancer.

17. Privo Technologies Inc

• Website: privotechnologies.com
• Ownership type: Private
• Headquarters: Peabody, Massachusetts, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Other (Grant), $2.5M, February 2022
• Founded year: 2016
• Headcount: 1-10
• LinkedIn: privo-technologies

Privo Technologies Inc, based in Peabody, Massachusetts, is a biotechnology firm founded in 2016. The company specializes in developing innovative cancer treatments that leverage advanced drug delivery systems. Their flagship products include PRV111, a topical chemotherapy patch, PRV131, an injectable for intratumoral use, and PRV211, designed for intraoperative chemotherapy. These products aim to provide safer and more effective treatment options for various cancers, including head and neck cancer and other solid tumors. Privo has received significant funding, including a $2 million grant from the FDA and over $20 million in non-dilutive funding from institutions like the National Cancer Institute. Their ongoing clinical trials and collaborations with regulatory bodies underscore their active role in the biotechnology industry, particularly in the targeted drug delivery space.

18. Shiftbio INC.

• Website: shiftbio.net
• Ownership type: Private
• Headquarters: Seoul, Seoul, South Korea
• Employee distribution: South Korea 100%
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: shiftbio

Shiftbio INC. is a biotechnology firm based in Seoul, South Korea, founded in 2020. The company focuses on creating innovative drug delivery systems and therapeutic development, particularly targeting rare and refractory diseases. Their natural drug delivery platform is designed to transform previously undruggable targets into viable therapeutic options. This platform is aimed at healthcare providers and pharmaceutical companies seeking advanced solutions for drug administration. Shiftbio's pipeline includes several programs that utilize their natural nanoparticle technology, which is noted for its low immunogenicity and high stability. The company has not reported any funding to date, indicating a self-sustained approach to its operations and development.

19. GenEdit

• Website: genedit.com
• Ownership type: Private Equity
• Headquarters: South San Francisco, California, United States (USA)
• Employee distribution: United States (USA) 96%, South Korea 4%
• Latest funding: Series A, $24.0M, January 2024
• Founded year: 2016
• Headcount: 11-50
• LinkedIn: genedit

GenEdit is a biotechnology firm based in South San Francisco, California, founded in 2016. The company is dedicated to developing innovative therapies through the targeted delivery of genetic medicines. With a focus on addressing significant healthcare challenges, GenEdit aims to provide advanced genetic therapies for patients suffering from conditions with high unmet medical needs, particularly in the immune and nervous systems. Their proprietary delivery platform, NanoGalaxy®, utilizes a library of polymer nanoparticles to enhance the delivery of genetic medicines, overcoming limitations faced by traditional methods. Recently, GenEdit secured $24 million in Series A funding and announced a multiyear collaboration with Genentech to develop novel nanoparticles for autoimmune diseases. This involvement in partnerships and funding rounds highlights their active engagement in the biotechnology sector and commitment to advancing targeted drug delivery solutions.

20. Precision NanoSystems is now part of Cytiva

• Website: precisionnanosystems.com
• Ownership type: Corporate
• Headquarters: Vancouver, British Columbia, Canada
• Employee distribution: Canada 100%
• Latest funding: June 2021
• Founded year: 2010
• Headcount: 51-200
• LinkedIn: precision-nanosystems-inc-

Precision NanoSystems, now integrated into Cytiva, is a biotechnology firm based in Vancouver, British Columbia. Founded in 2010, the company has carved out a niche in the development of lipid nanoparticle technologies that are pivotal for genomic medicines, particularly mRNA vaccines and therapeutics. They offer a full suite of services, from formulation development to cGMP manufacturing, catering primarily to biopharmaceutical companies focused on drug development across various diseases. Their innovative NanoAssemblr technology facilitates the efficient production of lipid nanoparticles, which are essential for delivering nucleic acid-based therapies. Precision NanoSystems has established itself as a key player in the biopharma sector, collaborating with numerous organizations to enhance the efficacy and safety of drug delivery systems.

21. The Whiteoak Group, Inc.

• Website: thewogroupinc.com
• Ownership type: Private
• Headquarters: Washington, D.C., District Of Columbia, United States (USA)
• Employee distribution: United States (USA) 76%, Hong Kong S.A.R 24%
• Founded year: 2014
• Headcount: 11-50
• LinkedIn: the-whiteoak-group-llc

The Whiteoak Group, Inc. is a biotechnology firm based in Washington, D.C., founded in 2014. With a team of around 17 employees, the company is dedicated to advancing drug delivery systems through its proprietary QTsome technology. This innovative platform is designed to enhance the delivery of nucleic acid-based therapeutics, such as oligonucleotides and siRNAs, particularly in oncology applications. The QTsome technology utilizes quaternary-tertiary lipoamine lipid nanoparticles, which are engineered to improve drug delivery efficiency and safety. The company collaborates with pharmaceutical firms and research institutions to tackle the challenges of drug delivery, aiming to provide solutions that minimize side effects while maximizing therapeutic impact. Their focus on nanotechnology and gene delivery positions them as a notable player in the biotechnology sector, particularly in the targeted drug delivery niche.

Targeted Drug Delivery Insights: Key Companies

Want to Find More Targeted Drug Delivery Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!